1. Home
  2. MREO vs FNGR Comparison

MREO vs FNGR Comparison

Compare MREO & FNGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mereo BioPharma Group plc

MREO

Mereo BioPharma Group plc

HOLD

Current Price

$0.25

Market Cap

50.3M

Sector

Health Care

ML Signal

HOLD

Logo FingerMotion Inc.

FNGR

FingerMotion Inc.

HOLD

Current Price

$0.19

Market Cap

50.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MREO
FNGR
Founded
2015
2016
Country
United Kingdom
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
50.3M
50.2M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
MREO
FNGR
Price
$0.25
$0.19
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$1.50
N/A
AVG Volume (30 Days)
5.2M
51.4M
Earning Date
05-11-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
16.67
N/A
EPS
N/A
N/A
Revenue
$500,000.00
$24,132,261.00
Revenue This Year
$5,184.20
N/A
Revenue Next Year
$55.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$0.15
52 Week High
$2.37
$2.20

Technical Indicators

Market Signals
Indicator
MREO
FNGR
Relative Strength Index (RSI) 36.56 43.50
Support Level $0.22 $0.16
Resistance Level $0.35 $0.37
Average True Range (ATR) 0.02 0.05
MACD -0.00 0.00
Stochastic Oscillator 12.61 6.46

Price Performance

Historical Comparison
MREO
FNGR

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About FNGR FingerMotion Inc.

FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company's business line includes Telecommunications Products and Services, Value Added Products and Services, Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.

Share on Social Networks: